| Session | Speaker | Presentation |
M1 |
Kwan Lee |
|
M-2 |
Wayne Anderson |
The Impact of Genomics Research on Drug Discovery and Development |
M-3 |
Xiaohong Huang |
|
M-4 |
Scott Chasalow |
|
M-5 |
Russ Wolfinger |
|
M-6 |
Tom Braun |
|
M-7 |
Peter F. Thall |
|
Keynote Address |
Carl Peck |
|
T-1 |
Ken Wilkins |
Allowing for Possibly Non-Ignorable Non-Response when Analyzing Longitudinal Outcomes in Clinical Trials: An Alternate Approach |
T-2 |
Dan O. Scharfstein |
|
T-3 |
Robert Goldberg-Alberts |
|
T-4 |
David Huang |
|
T-5 |
Frank Bretz |
|
T-6 |
Frank Harrell |
|
T-7 |
Leonard Oppenheimer |
|
W-FDA |
David Ross |
|
| W-FDA | Mark Rothmann | On Some Statistical Issues Involving Clinical Trials in Oncology |
| W-FDA | Rajeshwari Sridhara | Statistical Challenges in Oncology Drug Development |